Splenectomy for haemophagocytic lymphohistiocytosis of unknown origin: risks and benefits in 21 patients

Affiliations

• ¹ Laboratory of cellular and molecular mechanisms of hematological disorders and therapeutic implications, INSERM U1163, Imagine Institut, Sorbonne Paris University, Paris, France.
• ² Internal Medicine, Groupe Hospitalier Paris Seine Saint Denis, Hôpital Avicenne, AP-HP, Bobigny, France.
• ³ Hematology Department, Saint-Vincent Hospital, GHICL, Lille, France.
• ⁴ Service de Médecine Interne et Immunologie Clinique, Centre de référence des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000, Lille, France.
• ⁵ UMR CNRS 6015-INSERM U1083, Mitolab Team, MITOVASC Institute, University, Angers, France.
• ⁶ Department of Internal Medicine, Angers University Hospital, Angers, France.
• ⁷ CNRS-UMR 5164 Immuno ConcEpT, Bordeaux University, Bordeaux, France.
• ⁸ Department of Internal Medicine, Bordeaux University Hospital, Bordeaux, France.
• ⁹ Intensive Care Medicine, INSERM CIC 1415, CRICS-TriggerSep Research Network, CHRU de Tours, 37044, Tours, France.
• ¹⁰ Internal Medicine and Clinical Immunology, CHU Rennes, Rennes, France.
• ¹¹ Internal Medicine and Hematological Unit, Centre Hospitalier de Dax, Dax, France.
• ¹² Departement of Clinical Research, Paris Seine Saint Denis Hospital, Sorbonne Paris University, AP HP, Bobigny, France.
• ¹³ CHU de Bordeaux, Hôpital Saint-André, Service de Médecine Interne et Maladies Infectieuses and Université de Bordeaux, INSERM U1219, BPH, F-3300, Bordeaux, France.
• ¹⁴ Department of Clinical Hematology, Necker Children's Hospital, AP HP, Paris, France.